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Abstract
c-Jun activation domain-binding protein-1 (Jab1) acts as a modulator of intracellular signaling and affects cellular
proliferation and apoptosis, through its existence as a monomer or as the fifth component of the constitutive
photomorphogenic-9 signalosome (CSN5). Jab1/CSN5 is involved in transcription factor specificity, deneddylation of
NEDD8, and nuclear-to-cytoplasmic shuttling of key molecules. Jab1/CSN5 activities positively and negatively affect
a number of pathways, including integrin signaling, cell cycle control, and apoptosis. Also, more recent studies
have demonstrated the intriguing roles of Jab1/CSN5 in regulating genomic instability and DNA repair. The effects
of Jab1/CSN5’s multiple protein interactions are generally oncogenic in nature, and overexpression of Jab1/CSN5 in
cancer provides evidence that it is involved in the tumorigenic process. In this review, we highlight our current
knowledge of Jab1/CSN5 function and the recent discoveries in dissecting the Jab1 signaling pathway. Further, we
also discuss the regulation of Jab1/CSN5 in cancers and its potential as a therapeutic target.
Introduction
Through detailed knowledge of oncogenic signal trans-
duction pathways, targeted therapies have provided
exciting advancements in the treatment of cancer where
standard chemotherapy alone has failed. We discuss
here a potential therapeutic target, the c-Jun activation
domain-binding protein-1 (Jab1), which has been impli-
cated to be involved in the tumorigenic process. Jab1 is
involved in multiple protein interactions that affect
many stages of tumorigenesis and, therefore, has the
potential to be an effective therapeutic target.
Jab1/CSN5 was originally identified as a c-Jun coacti-
vator and subsequently discovered to be the fifth mem-
ber and an integral component of the constitutive
photomorphogenic-9 (COP9) signalosome (CSN) com-
plex, a multifunctional protein complex involved in
modulating signal transduction, gene transcription, and
protein stability in cells [1-3]. For this reason, Jab1 is
also referred to as CSN5. Jab1/CSN5 contains an Mpr1-
Pad1-N-terminal (MPN) domain metalloenzyme motif
(JAMM) that is essential for the CSN isopeptidase activ-
ity responsible for the deneddylation of the cullin-RING
ubiquitin ligases (CRLs) by CSN [4].
Jab1/CSN5 plays an essential role in positively regulat-
ing cellular proliferation by functionally inactivating sev-
eral key negative regulatory proteins and tumor
suppressors through their subcellular localization, degra-
dation, and deneddylation, including p53, Smad 4/7, and
the cyclin-dependent kinase inhibitor p27
Kip1 (p27)
[5-8]. It is also capable of stabilizing certain proteins,
including hypoxia-inducible factor 1a (HIF-1a)a n dc -
Jun, as well as acting as a transcriptional co-factor for
MYC, which is responsible for the transcriptional activa-
tion of genes involved in cell proliferation, angiogenesis,
and invasion [1,9,10]. Jab1/CSN5 overexpression has
been identified in a number of tumor types and has
been implicated in the initiation and progression of sev-
eral types of cancer.
Jab1/CSN5 structure and function
The Jab1/CSN5 gene is highly conserved and extensively
studied in mice. The murine Jab1/CSN5 gene is located
on chromosome 2, whereas the human Jab1/CSN5 gene
is located on chromosome 8 (Figure 1A). The human
Jab1/CSN5 protein consists of 334 amino acids and has
a molecular mass of 38 kDa (Figure 1A, B). While there
are two Arabidopsis Jab1/CSN5 homologue genes, AJH1
and AJH2, there is only one known isoform in humans
[11,12]. Jab1/CSN5 is evolutionarily conserved in
humans, mice, fission yeast, and plants, which provides
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reproduction in any medium, provided the original work is properly cited.Figure 1 Structure of the Jab1/CSN5 gene and domains of the Jab1/CSN5 protein. (A) Schematic of the Jab1/CSN5 gene which is 33 kb
long and localized at chromosome 8Q13.2. (B) The 8 exons within the 334 amino acid sequence are shown. (C) Schematic of Jab1/CSN5
consists of 334 amino acids with a Jab1/CSN5/MPN domain metalloenzyme (JAMM)-containing Mpr1-Pad1-N-terminal (MPN) domain and a
nuclear export signal (NES) domain close to the p27 binding domain (PBD) at the C-terminal end.
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proliferation [13-15]. Jab1/CSN5 was linked to the CSN
through the discovery that the fifth member of the CSN
was, in fact, Jab1/CSN5 and also when AJH1 and AJH2,
which encode subunit 5 of the CSN, were identified in
Arabidopsis [11,12,14]. Jab1/CSN5 has subsequently
been termed the CSN subunit 5 (CSN5) [16].
Jab1/CSN5 is present in the large CSN holocomplex,
smaller complexes, and as a monomer in Arabidopsis,
Drosophila, and mammalian cells [8,12,17,18]. Whereas
CSN-associated Jab1/CSN5 is located primarily in the
nucleus, free-form Jab1/CSN5 can be both cytoplasmic
and nuclear. Attempts to further study the presence of
Jab1/CSN5 in these complexes have been made. Separa-
tion of the CSN and the smaller complex by gel filtra-
tion method or by the nondenaturing polyacrylamide gel
electrophoresis (native-PAGE) technique has proven to
be a valuable tool for analyzing the presence of Jab1/
CSN5 in these complexes [8,17,19]. These studies have
provided valuable information about the localization and
stability of Jab1/CSN5; however, the overall picture of
when Jab1/CSN5 as a member of the large or small
complex or in its free form and the effect on various
cellular processes remains to be studied.
The domains responsible for Jab1/CSN5’si n t e r a c t i o n
with p27 and its metalloproteinase activity have been
identified and are shown in Figure 1C. Jab1/CSN5
directly binds to p27 and mediates p27’ss h u t t l i n g
between the nucleus and the cytoplasm in a CRM1-
dependent manner through a nuclear export signal
(NES)-like sequence between amino acids 233 and 242
at its C-terminal end [8]. Jab1/CSN5 has a Mpr1-Pad1-
N (MPN) terminal domain that contains a Jab1/CSN5
MPN domain metalloenzyme (JAMM) motif (also
known as the MPN+ motif). It has been postulated that
the Jab1/CSN5 MPN domain serves as a protein-protein
platform, while the JAMM motif acts as a cofactor for
enzymatic activity [20]. The JAMM motif within Jab1/
CSN5 appears to be key to CSN deneddylation activity,
but deneddylation is still reliant on the entire CSN com-
plex, as the loss of any one of the CSN subunits results
in loss of this activity [20]. The JAMM motif is required
for Jab1/CSN5’s co-activation of the oncogenic MYC
transcription factor and for Jab1/CSN5’s transformative
effects in a breast epithelial model, this was also found
to be dependent of the assembly of the entire COP9 sig-
nalosome [21]. This domain does not, however, appear
to be critical to Jab1/CSN5’s functions outside of the
full CSN, such as the stabilization of HIF-1a and its role
as a co-factor for E2F1 apoptotic function [9,22]. In fact,
the domains responsible for many of Jab1/CSN5’s inter-
actions and the mechanism by which it performs its
many functions, as well as the involvement of the COP9
signalosome or small complex, remain to be determined.
Elucidation of these domains will provide important
insights that will further characterize the mechanisms of
Jab1/CSN5 as well as the CSN.
Jab1/CSN5 is a member of the CSN
The CSN is a multisubunit complex that controls pro-
tein stability by regulation of the CRL family and is also
a regulator of many cellular and developmental pro-
cesses, including cell-cycle control, transcription, and
DNA-damage response (please refer to reviews for more
detailed information [20,23-25]. The CSN consists of 8
subunits and forms a large, 450- to 550-kDa holocom-
plex as well as smaller (250- to 300-kDa) cytoplasm-
localized complexes containing a subset of CSN subu-
nits (CSN-4, -5, -6, -7b, and -8 in mammals) [8,17,26].
Jab1/CSN5 is one of two members of the CSN that con-
tain the MPN domain.
Jab1/CSN5 is a key CSN subunit, able to integrate
multiple functions of the CSN complex [3]. The CSN
regulation of the CRL family of ubiquitin E3 complexes
relies on its deneddylation function [23,27,28]. The
JAMM domain present within Jab1/CSN5 which is the
catalytic center for the CSN’s cleavage of the ubiquitin-
like protein Nedd8 from the Cul1 subunit of the SCF
ubiquitin ligases [4] is the same domain present in the
26S proteasome lid component, RPN11, and is responsi-
ble for the proteasome’s cleavage of the ubiquitin sub-
strate [29,30]. Jab1/CSN5 alone does not have
metalloproteinase activity; other CSN subunits, or per-
haps the entire complex, are required for this deneddy-
lase activity [4,23,25]. The JAMM domain also has
deubiquitinase activity, which regulates ubiquitinated
protein sorting into exosomes when Jab1/CSN5 is asso-
ciated with the CSN [31]. This links the CSN with the
regulation of ubiquitinated proteins that are transferred
by exosomes, a process that impacts the flow of infor-
mation from neighboring or distant cells.
Jab1/CSN5 as a coactivator
Jab1/CSN5 was initially identified as a coactivator of c-
Jun, a member of the activating protein-1 (AP-1) com-
plex [1]. Members of the Jun (c-Jun, JunB, JunD) and
Fos (c-Fos, FosB, Fra-1 and Fra-2) families form the AP-
1 complex, which acts as a mitogen-activated composite
transcription factor that has binding sites know as TPA
(phorbol diester, 12-O-tetradecanoylphorbol-13-acetate)-
responsive element (TRE) in a variety of promoters that
activate various target genes. The AP-1 complex can
respond immediately to many different extracellular sti-
muli, such as tumor-promoting TPA, epidermal growth
factor (EGF), and serum [32]. Although c-Jun and c-Fos
have very similar DNA binding and dimerization
domains, they seem to activate distinct sets of target
genes that only partially overlap [33-35]. Jab1/CSN5 can
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off-rate of c-Jun and JunD with its cognate AP-1 DNA
binding sites and potentiate c-Jun transactivation; how-
ever, Jab1/CSN5 does not affect JunB or v-Jun binding
[1]. Jab1/CSN5’s stabilization of c-Jun offers a mechan-
ism of specificity in the binding of c-Jun to target genes.
Jab1/CSN5 is involved in c-Jun-induced, AP-1-
mediated transcriptional activation through its interac-
tion with c-Jun as well as affecting the interaction
between c-Jun and other binding partners [1,36-38].
Jab1/CSN5 affects other proteins and their interaction
with c-Jun by binding directly to and changing their
sub-cellular localization. These interactions have been
identified with the following proteins and in general
lead to activation of AP-1: lymphocyte function-asso-
ciated antigen-1 (LFA-1) [36,39], macrophage migration
inhibitory factor (MIF) [40], hepatopoietin [41], and
hepatitis B virus X protein (HBx) [42]. c-Jun is a well
known oncogene whose aberrant expression and activity
have been detected in cancer [32,43-46]. Because c-Jun
expression is autoregulated, one can imagine that Jab1/
CSN5, as a c-Jun-coregulator, may reinforce this posi-
tive-feedback loop at the transcriptional level and drive
c-Jun protein expression further to promote
tumorigenesis.
Jab1/CSN5’s involvement as a specificity factor has
been demonstrated for a number of proteins in addition
to c-Jun. Jab1/CSN5 is a transcriptional coactivator and
potential specificity factor for nuclear factor-kappaB
(NF-B), p53 binding protein 1 (53BP1), Brain-2 (Brn-
2), and heart and neural crest derivatives expressed 2
(HAND2) signaling [37,47-50]. Jab1/CSN5 also has been
shown to interact with the proto-oncogene Bcl-3, a
member of the IB family of inhibitory proteins and is
present predominantly in the nucleus. While most
members of the IB family act to inhibit NF-B, Bcl-3
can activate NF-B transcription. Jab1/CSN5 binds to
Bcl-3 to enhance NF-B, p50, and DNA complex forma-
tion and may link NF-B and AP-1 gene transcription
[47]. Another example of Jab1/CSN5 as a specificity fac-
tor is its binding to the HAND2 HLH domain and stabi-
lization of the HAND2-E-protein 12 complex on DNA
and potential involvement in promoting gene expression
during neuronal development [50]. Jab1/CSN5 was also
found to bind directly to 53BP1 and, under mitotic
stress conditions, is required for the hyperphosphoryla-
tion resulting in activation of the mitotic checkpoint
mechanism [48]. Interaction of Jab1/CSN5 with Brn-2, a
transcription factor expressed in the developing neocor-
tex, was postulated to play a role in Brn-2-related neu-
ronal development and, potentially, in the development
of neurodegenerative diseases such as Parkinson’sd i s -
ease and Alzheimer’s disease [49]. Jab1/CSN5 also acts
as a bridge between coactivators and receptors in the
progesterone receptor-steroid receptor coactivator com-
plex [37].
These studies provide evidence of the role of Jab1/
CSN5 as a specificity factor, yet the mechanism by
which it acts is poorly defined. Phosphorylation is one
mechanism of regulation that could be attributed to
Jab1/CSN5’s activation of kinases such as the Jun N-
terminal kinase (JNK), which was reported to lead to
increased phosphorylation of c-Jun, or through activa-
tion of kinases associated with the CSN [51,52]. Other
transcription factors phosphorylated by the CSN include
AP-1 and NF-kB. Also, the CSN itself has been charac-
terized as a transcriptional regulator, recent data suggest
that the CSN may be associated with chromatin [24].
Another mechanism involves the CSN’sr e g u l a t i o no f
protein stability through ubiquitination of transcription
factors. Whether Jab1/CSN5 functions independently as
specificity factor or is mediated by functions of the
COP9 signalosome has yet to be determined.
Jab1/CSN5 a positive regulator of cell cycle progression
Jab1/CSN5 promotes cell proliferation by interacting
directly with p27
Kip1 (p27) and induces nuclear export
and subsequent p27-degradation. p27 is a critical com-
ponent of the cell-cycle machinery [53]. As an inhibitor
of cyclin E-Cdk2, p27 plays a pivotal role in controlling
cell proliferation and therefore the cell’se n t r yi n t oS
phase and exit from G1 phase during development and
tumorigenesis [54,55]. Although p27 is haploinsufficient
for tumor suppression, low levels of the protein have
been identified in several cancers [56]. In addition, p27’s
cytoplasmic translocalization has been observed in
human tumors and is associated with poor survival
[57-61]. Jab1/CSN5’s nuclear to cytoplasmic shuttling of
p27 play an important role in the regulation and func-
tion of p27. Accumulation of cytoplasmic p27 results in
increased cell motility and migration through its interac-
tion with RhoA, a GTPase that regulates cell motility by
reorganization of actin filaments [62,63]. Therefore
Jab1/CSN5’s role in p27 cellular localization interrupts
p27’s inhibitory effect on cellular proliferation and also
puts it in position to interact with RhoA to mediate cell
motility and migration which has an overall tumorigenic
effect on the cell. In post-translational control, Jab1/
CSN5–either alone or as a member of the CSN–plays
an important role as a mediator of nuclear export and
subsequent degradation of p27. Other Jab1/CSN5 inter-
actions also act to enhance or inhibit Jab1/CSN5-
mediated p27 degradation and are listed in Table 1.
Jab1/CSN5 as a modulator of intracellular signaling
Jab1/CSN5 binds numerous proteins, generally resulting
in cell proliferation, survival and in some cases angio-
genesis and invasion. Table 2 summarizes these
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intracellular distribution, as a transcriptional activator, a
member of the COP9 signalosome as well as novel Jab1/
CSN5 interactions. Certainly, Jab1/CSN5’sr o l ei n
nuclear to cytoplasmic shuttling and subsequent degra-
dation is widely known and affects many important pro-
teins and tumor suppressors including p27, p53, and
Smad 7, to name a few. Figure 2 outlines many of these
interactions that act to positively or negatively regulate a
number of signaling pathways in the cell.
Jab1/CSN5 affects transforming growth factor-b (TGF-
b) signaling by inducing degradation of two key down-
stream molecules, Smad4 and Smad7. Although TGF-b
signaling can be tumor suppressive by inducing cell
cycle arrest, differentiation, and apoptosis, it can be
influenced by various factors in the tumor microenvir-
onment as well as the tumor itself to, in fact, promote
growth, invasion, and metastasis and contribute to the
tumorigenic process [64,65]. The receptor-regulated
Smad proteins (R-Smads) mediate TGF-b signaling
through binding the common Smad, Smad 4, translocat-
ing to the nucleus, and mediating transcription of var-
ious genes [66]. Negative regulation of TGF-b signaling
by inhibitor Smads (I-Smads), including Smad6 and
Smad7, acts to interfere with the activation of the R-
Smads [67,68]. Jab1/CSN5-induced Smad4 degradation
results in reduced TGF-b-mediated gene transcription,
whereas its degradation of Smad7 leads to enhanced
TGF-b signaling effects [7,69]. It is therefore possible
that connections exist between Jab1/CSN5 and TGF-b
signaling that likely involve the COP9 signalosome. It is
possible that overexpression of Jab1/CSN5 during the
tumorigenic process results in enhanced TGF-b signal-
ing that contributes to the progression of the disease.
Jab1/CSN5 has been implicated in apoptosis, DNA
checkpoint and damage repair through a number of
these protein interactions. Jab1/CSN5 can mediate the
nuclear export and cytoplasmic degradation of the
tumor suppressor p53 and enhances MDM2-mediated
p53 ubiquitination [6]. It also mediates the degradation
of the Rad9-Rad1-Hus (9-1-1) complex, thus impairing
DNA checkpoint and repair in response to damage [70].
Recently, loss of Jab1/CSN5 results in spontaneous
DNA breaks that was associated with increased expres-
sion of the histone H2AX, which recognized DNA dou-
ble strand breaks and initiates recruitment of DNA
damage repair proteins [71]. This is coupled with a defi-
ciency in homologous recombination repair due to
decreased Rad51 expression and function [71]. Taken
together, these interactions provide evidence of Jab1/
CSN5 as an inhibitor of DNA checkpoint and damage
repair and an instigator of apoptosis. However, Jab1/
CSN5’s interaction with the transcription factor E2F-1
acted to synergistically induces apoptosis [22].
An interesting connection between Jab1/CSN5 and the
hypoxia-inducible factor 1 alpha (HIF-1a) highlights
Jab1/CSN5’s potential involvement in the angiogenic
pathway. HIF-1a is an oxygen-dependent transcriptional
activator that is rapidly degraded under normoxic condi-
tions, but under hypoxic conditions, it acts as a master
regulator of a number of hypoxia-inducible genes,
including those that are involved in angiogenesis and in
cell proliferation, survival, and metabolism [72]. Jab1/
CSN5 was found to compete with p53 to bind directly
to the oxygen-dependent death domain of HIF-1a, lead-
ing to stabilization of HIF-1a by blocking hypoxia-
dependent p53-mediated degradation [9]. In addition to
stabilization of HIF-a, Jab1/CSN5 binding results in an
increase in its transcriptional activity, resulting in
increased VEGF expression [9]. This interaction between
Jab1/CSN5 and HIF-1a suggest that Jab1/CSN5 is
involved in the angiogenic pathway.
Taken together, many of these interactions are onco-
genic and result in aberrant signaling involved in cell
cycle progression, TGF-b signaling, angiogenesis, DNA
checkpoint and repair, and apoptosis. These interactions
themselves are often ill defined, and the role of the
COP9 signalosome is not always clear. Further studies
will need to be undertaken to identify the exact
mechanisms taking place and to better define the role of
Jab1/CSN5 in normal developmental processes as well
as in tumorigenesis.
Regulation of Jab1/CSN5’s activity
One of the potentially oncogenic mechanisms of JAB1/
CSN5 overexpression is through gene amplification by
Table 1 Jab1/CSN5-interacting proteins that regulate p27
Protein Description Interaction effect References
PGP9.5 Ubiquitin C-terminal hydrolase p27 degradation [103]
Thioredoxin Cellular redox enzyme that regulates cell growth
and apoptosis
Inhibits Jab1/CSN5-mediated AP-1 transactivation and
Jab1/CSN5-dependent p27 degradation
[104]
VDUP1 Tumor suppressor and stress response gene,
vitamin D3 up-regulated protein-1
Inhibits Jab1/CSN5-mediated AP-1 transactivation and
Jab1/CSN5-dependent p27 degradation
[105]
Hepatitis B virus pre-S2
mutant surface antigen
Hepatitis B virus large antigen mutant associated
with hepatocellular carcinogenesis
p27 degradation [106]
Abbreviations: PGP9.5, Protein gene product 9.5; AP-1, activator-protein 1; VDUP1, Vitamin D3 up-regulated protein 1.
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Protein Description Effect of Jab1/CSN5 interaction Overall signaling effect References
Proteins degraded by Jab1/CSN5
p27 Cyclin-dependent kinase inhibitor and tumor
suppressor
Nuclear export and degradation Increased cellular proliferation [8]
LHR Lutropin/choriogonadotropin receptor Degradation Reproductive disorders [38]
p53 Transcription factor and tumor suppressor Nuclear export and degradation Inhibit p53 tumor suppressor
function
[6,107,108]
Smad 4 Co-Smad, positive regulator of TGFß signaling Ubiquitination and degradation Inhibit TGFß signaling [7]
Smad 7 Inhibitory Smad, negative regulator of TGFß
signaling
Nuclear export and degradation Increase TGFß signaling [69]
ERa Estrogen receptor a Degradation Increase hormone induced
transcription
[109]
West nile virus
Capsid
Activates caspase-3 and caspase-9 in the
apoptosis pathway
Nuclear translocation and
degradation
Protective against West Nile Virus [42]
Cyclin E Cell cycle control, G1 to S phase Degradation Cell cycle [110]
Rad9-Rad1-Hus
complex
Involved in DNA damage sensing and DNA
repair
Degradation Impair DNA checkpoint and
repair response to DNA damage
[70]
RUNX-3 Runt-related transcription factors Nuclear export and degradations Inhibition of a tumor suppressor [111]
MIF Cytokine with tautomerase and
oxidoreductases activities
Inhibition of MIF secretion Inhibits MIF-mediated AKT
signaling
[112]
DNA
topoisomerase
(topo) II alpha
Enzyme that is essential for cell proliferation
that segregates chromosome pairs during
chromosome condensation
Degradation in a MPN dependent
manner under glucose starvation
Decreased cell proliferation
under stress conditions such as
glucose starvation
[113]
Endothelin
type A and B
receptors
G protein-coupled receptors whose
overexpression is correlated with chronic heart
failure and in infiltrating cells of atherosclerotic
lesions
Ubiquitination and degradation Decreased Endothelin-1 induced
intracellular signaling through
ERK1/2
[114]
Proteins affected by Jab1/CSN5
c-Jun Member of the AP-1 transcription factor family Transcriptional co-activator and
specificity factor
Increased transcriptional activity
and cellular proliferation
[1]
Myc Oncogenic transcription factor Promotes transcription of MYC
target genes and induces MYC
ubiquitination and turnover
Activates a wound signature and
induced cell proliferation and
invasion in breast cancer cells
[10]
HIF-1a Hypoxia inducible factor a Competes with p53 for binding,
stabilizes protein HIF-1a levels
Increased expression of VEGF
and angiogenesis
[9,115]
HAND2 Transcription factor important for development
of the heart, limbs, and neural crest-derived
lineages
Enhances HAND2 DNA binding Tissue-specific transcription [50]
53BP1 P53 binding protein, cellular response to stress
conditions
Hyperphosphorylation under
stress conditions
Activation of mitotic checkpoint
mechanism
[48]
Smad 5 Receptor associated Smad protein, positive
regulator of TGFß signaling
Inhibits bone morphogenetic
signaling
Affect matrix turnover [116]
Brn-2 POU transcription factor, development of
neocortex and neural cell lineage
Increases Brn-2 transcriptional
activity
Neuronal development and
neurodegenerative diseases
[49]
Bcl-3 Member of I-B family, proto-oncogene, can
activate or inhibit NF-B transcription
Bridges binding between Jab1/
CSN5 and NF-B
Link NF-B and AP-1 gene
activation
[47]
E2F-1 Transcription factor important for cell cycle
progression, DNA damage repair, apoptosis
Cofactor for E2F-1 dependent
apoptosis, but not cell cycle entry
Enhances E2F-1 mediated
apoptosis
[22]
PR, SRC-1 Progesterone receptor, steroid receptor
coactivator
Stabilized PR-SRC-1 complexes Increased transcriptional activity [37]
SMYD3 A histone methyltransferase Suppressed transcription of the
tumor suppressor p16
Negative regulation of p16 and
possible increased in
hematopoietic progenitors
[86]
Cullin Subunit of SCF ubiquitin ligases Cleavage of NEDD8 from Cul1 Required for optimal SCF
ubiquitin ligase activity
[4]
PAR-2 G protein-coupled receptor for trypsin and
tryptase
Increased PAR-2 transcription Increased AP-1 activation [117]
MDM2 Mediates p53 degradation Reduces MDM2 self-
ubiquitination
Negative regulation of p53 [108]
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locus is located on chromosome 8q13.1, a region that is
frequently amplified in breast, prostate, colorectal and
ovarian cancers [73-77], which has also been linked to
aggressive cancer phenotypes and metastatic progression
[10,78].
A few proteins have been shown to regulate Jab1/
CSN5 levels, localization, or activity (Table 2). Psoriasin
(S100A7), a small calcium-binding protein that is highly
expressed in early breast cancer, enhances Jab1/CSN5
activity and promotes tumorigenesis [79,80]. Overex-
pression of psoriasin increases nuclear Jab1/CSN5 activ-
ity, resulting in increased AP-1 activity and reduced p27
expression [80]. The human epidermal growth factor
receptor 2 (HER2) oncogene increases expression of
Jab1/CSN5 through the AKT signaling pathway via the
binding of the transcription factor b-catenin and tran-
scription factor 4 (TCF-4) to the Jab1/CSN5 promoter
[81]. Treatment with wortmannin, a phosphoinositide 3-
kinase (PI3K)/AKT inhibitor, subsequently reduced
Jab1/CSN5 expression [81]. Additionally, the oncogenic
tyrosine kinase Bcr-Abl, which is a key contributor to
the development of chronic myelogenous leukemia
(CML), was found to be another key regulator of Jab1/
CSN5 [82]. Bcr-Abl-expressing cells have higher levels
of a cytoplasmic Jab1/CSN5-containing small complex
were reduced on inhibition of the Bcr-abl kinase, the
mitogen-activated protein (MAP) kinase, and the PI3K
signaling pathways [82]. In another study, the peroxi-
some proliferator-activated receptor g (PPAR g)
suppressed Jab1/CSN5 promoter activity in both PPAR
g-dependent and -independent manners [83]. These stu-
dies have linked Jab1/CSN5 expression and activity with
well-known oncogenes and suggest that Jab1/CSN5
activities are involved in the progression of cancer.
However, these oncogenes are fairly cancer specific and
given the wide range of cancers that Jab1/CSN5 is
found to be overexpressed, it is quite possible that other
mechanisms or regulation of Jab1/CSN5 expression
exists.
Jab1/CSN5 in mouse models
Jab1/CSN5-deficient mice exhibit an embryonically
lethal phenotype, which suggests that Jab1/CSN5 is
important in development and survival. Jab1/CSN5-
null embryos are viable up through the blastocyst
stage but begin to exhibit disrupted development at
embryonic day 6.0 and are no longer viable at day 8.5,
before gastrulation occurs [71,84]. Several targets of
Jab1/CSN5, including p27, p53, c-myc, and cyclin E,
were found to be highly expressed in Jab1/CSN5
-/-
embryos, resulting in impaired proliferation and accel-
erated apoptosis [71,84]. By building on these findings,
we found that Jab1/CSN5 sensitized mouse embryonic
fibroblasts to gamma radiation-induced apoptosis and
increased spontaneous DNA damage that could be
attributed to reduced levels of the DNA repair protein
Rad51 and increased levels of p53 [71]. We found that
in the absence of exogenous DNA damage, Jab1/
CSN5-deficient embryos and osteosarcoma cells
showed increased incidence of a spontaneous genome
instability phenotype: findings included a large num-
ber of TUNEL foci in Jab1/CSN5-null embryos
embryos and blastocysts and an increased number of
g-H2AX foci with a decreased percentage of intact
DNA in Jab1/CSN5-deficient mouse embryonic fibro-
blasts and in human osteosarcoma cells [71]. These
findings suggested that Jab1/CSN5-deficient cells pro-
mote spontaneous DNA breaks; therefore, loss of
Jab1/CSN5 may affect efficient DNA repair. The
results of these studies indicate that Jab1/CSN5 is
essential for efficient DNA repair and mechanistically
link Jab1/CSN5 to the maintenance of genome integ-
rity and to cell survival.
Table 2 Proteins that interact with Jab1/CSN5 (Continued)
TRAF-2 TNFR-associated factor 2, mediator of TNFa
prosurvival response
Ubiquitination of TRAF-2 Necessary for TNF-a prosurvival
signaling and MMP production
[118]
Rad51 DNA repair protein involved in homologous
recombination
Increases expression through
negative regulation of p53
Increased ability of cell to repair
DNA
[71]
FcaRI/CD89 Receptor for IgA expressed on myeloid cells
and involved in phagocytosis, Ab-dependent
cellular cytotoxicity, antigen presentation, and
cytokine release
Binds directly to the intracellular
domain and is involved in
regulating stabilization of surface
expression
Decreased expression of FcaR1
and possible defective antigen
recognition response
[119]
5-HT(6)R Serotonin receptor involved in the control of
mood and emotion as well as involved in
neurological disorders
Reduced Jab1/CSN5 expression
decreases expression and activity
Reduced signaling through 5-HT
(6)R, increased c-Jun activity and
enhanced cell survival under
hypoxia
[120]
Abbreviations: 5-HT(6)R, serotonin 6 receptor; AP-1, activator protein ; Bcl-3, B-cell lymphoma 3-encoded protein; ERa, estrogen receptor a;F c aRI, FCalphaRI;
HAND2, heart- and neural crest derivatives-expressed protein 2; HIF-1a, hypoxia inducible factor a; LHR, lutropin/choriogonadotropin receptor; MIF, macrophage
migration inhibitory factor; MDM2, murine double minute; NEDD8, neural precursor cell-expressed developmentally down-regulated; NF-kB, nuclear factor kappa-
light-chain-enhancer of activated B cells; 53BP-1, p53 binding protein 1; PAR-2, abnormal embryonic PARtitioning of cytoplasm 2; PR, Progesterone receptor; SCF,
Skp1-Cullin-F-box; SRC-1, steroid receptor coactivator 1; TRAF-2, TNF receptor-associated factor 2; VEGF, vascular endothelial growth factor.
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role in cell cycle regulation, apoptosis, and DNA repair
processes that are critical for developing thymocytes
[85]. Conditional deletion of Jab1/CSN5 in thymocytes
resulted in defective S-phase progression and increased
apoptosis that could be attributed to CSN substrates,
including p53, IB-a,a n db-catenin. These results con-
firmed the importance of Jab1/CSN5 in coordinating the
process involved in the development and positive selec-
tion of T cells. Further, these findings provided some
support for the conceptual premise that Jab1/CSN5,
along with the rest of the CSN, orchestrates the devel-
opment of various tissues by maintaining the balance
between proliferation and survival throughout various
checkpoints in the process.
Overexpression of Jab1/CSN5 in a transgenic mouse
model was linked to myeloproliferative disease. Those
mice showed enhanced proliferation and maintenance of
hematopoietic progenitors [86]. Inversely, the results
from additional studies suggest that inhibition of Jab1/
CSN5 by siRNA results in delayed tumor growth in
murine xenografts, a finding that justifies further investi-
gation of Jab1/CSN5 as a potential therapeutic target
[87].
Jab1/CSN5 in cancer
Jab1/CSN5 has been implicated in the pathogenesis in
several cancer types and in many cases, specifically cor-
related with reduced levels of p27 and poor prognosis.
Because of emerging recognition of its role in negatively
controlling p27 activity, recent pre-clinical studies have
implicated Jab1/CSN5 function in the pathogenesis of
human cancers. Tumors in which Jab1/CSN5 overex-
pression was detected are listed in Table 3. Low levels
of p27 protein have been associated with high expres-
sion of Jab1/CSN5 in a number of tumors (Table 3).
Low p27 levels have been reported in up to 50% of all
human cancers, yet no modifications in the gene have
been identified, and inhibition of p27 is postulated to
occur at the post-transcriptional level [88,89]. In addi-
tion to low levels of p27 expression characterizing many
tumors, studies have increasingly pointed to subcellular
Figure 2 Regulation and targets of Jab1/CSN5.G r e e na r r o w sa n dp l u s( + )s i g n si n d i c a t eJ a b 1 / C S N 5 - p o s i t i v ei n t e r a c t i o n ;r e da r r o w sa n d
minus (-) signs indicate Jab1/CSN5-negative interaction. Abbreviations: AP-1, activator protein 1; HIF-1a, hypoxia inducible factor-1 a; MDM2,
murine double minute 2; PR, progesterone receptor, SRC-1, steroid receptor coactivator 1; TRC8, translocation in renal carcinoma
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Page 8 of 14localization of p27 through cytoplasmic translocation in
human tumors associated with poor survival rates
[57-61,90,91].
Jab1/CSN5-mediated degradation of p27 appears to be
a critical mechanism of regulation for this cell cycle
inhibitor. The correlation between high Jab1/CSN5
levels and low p27 levels in a number of tumors pro-
vides further evidence that this is a common phenom-
enon and may contribute to the pathogenesis of these
diseases. For example, Jab1/CSN5 expression was found
low or absent in normal adult breast tissue, but is aber-
rantly expressed in 50% of primary breast tumors and
90% of metastatic lesions making an ideal target for
therapeutic intervention [92,93]. Our group examined
Jab1/CSN5 and p27 protein expression in invasive breast
carcinoma specimens and their association with clinical
outcome [92,93]. We immunohistochemically detected
J a b 1 / C S N 5i n4 3( 8 1 % )o f5 3t u m o r s ,w i t h3 2( 6 0 % )
tumors having high levels of Jab1/CSN5 expression
(>50% of cells positive for Jab1/CSN5), but reduced or
absent p27 expression (P =0 . 0 2 ) .B r e a s tt u m o r sw i t h
high levels of p27 expression were rarely positive for
Jab1/CSN5 expression. Furthermore, Jab1/CSN5 protein
expression levels were higher in oncogenically trans-
formed breast cells and tumors than in normal mam-
mary epithelial specimens. Furthermore, adenovirally
mediated Jab1/CSN5 overexpression in breast cancer
cells reduced p27 expression levels by accelerating p27
degradation. Importantly, patients with Jab1/CSN5-nega-
tive tumors had no evidence of relapse or disease pro-
gression at a median follow-up duration of 70 months
[92]. These results correlate with the known molecular
function of Jab1/CSN5 in relocalizing p27 from the
nucleus to the cytoplasm, thereby promoting degrada-
tion of p27 through the ubiquitin/proteasome pathway,
allowing breast tumor cells to progress into S phase.
There were also a small number of cases in which high
Jab1/CSN5 expression did not correlate with low p27
expression. Other factors, such as the ubiquitin ligase, S-
phase kinase-associated protein 2 (Skp2), are known to
regulate p27 and have also been found to correlate with
p27 expression in cancer. In one study, Skp2 expression
correlated with reduced p27 in epithelial ovarian tumors,
and although Skp2 alone was associated with poor prog-
nosis, evaluation of the combined phenotype, Skp2(+)
Jab1/CSN5(+) p27(-), led to identification of patients
with the worst prognosis [94]. Given the importance of
p27 degradation in cancer, development of a therapy to
inhibit Jab1/CSN5 is likely to be clinically valuable.
While the connection between Jab1/CSN5 overexpres-
sion and reduced p27 is evident in human tumors, the
correlation between Jab1/CSN5 and c-Jun activation,
while apparent in preclinical studies, has yet to be vali-
dated in human specimens. Jun is a well-characterized
oncogene that has been demonstrated to promote cellu-
lar proliferation and invasion in certain tissues [95,96].
Expression of c-Jun is evident and has proven to have
prognostic value in a number of tumor types and to
contribute to carcinogenesis [43-46]. Further, c-Jun is
also downstream of a number of signaling cascades and
therefore contributes to the process of oncogenesis even
when expressed at normal levels [34]. While the link
between Jab1/CSN5 overexpression in tumors and c-Jun
activation has not been clearly identified in patient sam-
ples, our preclinical studies suggest that this correlation
exists. High AP-1 activity was detected in Jab1/CSN5
overexpressing xenograft models (data not shown).
Future studies to investigate this correlation in tumor
samples would be useful in validating these findings.
Importantly, Jab1/CSN5/CSN5, alongside Myc, was
found to act as a master regulator of a wound gene
expression signature in breast cancer cells. This study
suggests that Jab1/CSN5 plays an important role in
translating the cell stress response to transcription of
response genes that are involved in proliferation and
matrix invasiveness [10]. Jab1/CSN5’sl o c a t i o no nc h r o -
mosome 8q, which is frequently amplified during the
progression of cancer and its function as a master regu-
lator alongside Myc highlight the possibility that Jab1/
CSN5 is a candidate oncogene. This DNA copy number
gain of Jab1/CSN5 was confirmed in a study of hepato-
cellular carcinoma that correlated with amplification of
the 8q region [97]. This suggests that the location of
Jab1/CSN5 in this highly amplified region may be one
mechanism leading to its overexpression in cancer.
Jab1/CSN5’s role in breast cancer is increasingly
becoming clearer. Studies have demonstrated Jab1/
CSN5 overexpression in breast cancer [92,98,99]. The
breast cancer driving EGFR receptors including the
oncogenic HER2/neu have been correlated with
increased Jab1/CSN5 expression in clinical samples
[98,99]. Jab1/CSN5 was shown to be a target of EGFR
signaling in estrogen receptor-alpha-negative (ERa
-)
breast cancer and the translocation of Jab1/CSN5 to the
nucleus was shown to be mediated through the ERK sig-
naling pathway [98]. Similarly, HER-2/neu was found to
activate Jab1/CSN5 expression through the AKT/bet-
catenin pathway [99]. The involvement of Jab1/CSN5 in
breast tumorigenesis appears to be linked to the expres-
sion of EGFR and HER-2/neu receptors and may in part
mediate downstream signaling events that contribute to
the progression of tumor growth.
The detection of Jab1/CSN5 overexpression in a variety
of human tumors suggests that it is a significant contribu-
tor to the tumorigenic process. Results from preclinical
studies (and unpublished data) also provide evidence that
Jab1/CSN5 is playing an important role in this process
(references in Table 3). In a recent study by Adler et al,
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breast epithelial transformation and also linked the bio-
chemical activities of Jab1/CSN5. They found that Jab1/
CSN5 indeed had transforming capabilities that was
dependent on both the assembly of the COP9 signalosome
and also the isopeptidase activity present in JAMM motif
of Jab1/CSN5 [21]. Jab1/CSN5 is found to be overex-
pressed in a number of human tumors, but whether this
overexpression is sufficient to mediate the tumorigenic
process was tested in a transgenic mouse model. Intrigu-
ingly, mice overexpressing a modified Jab1/CSN5 show
that the level of Jab1/CSN5 expression is a critical deter-
minant of the proliferation and maintenance of hemato-
poietic progenitor cells in vivo, which may explain how
the overexpression of Jab1/CSN5 contributes to tumor
development [86]. It was postulated that perhaps an initial
DNA damaging event, activation of an oncogene or alter-
natively inhibition of a tumor suppressor could be neces-
sary for Jab1/CSN5 to mediate its tumorigenic effects.
Additional studies suggest that depletion of Jab1/CSN5 is
able to reduce proliferation in pancreatic cancer cells
[100]. These data suggest that overexpression of Jab1/
CSN5 contributes to the development of tumors and that
inhibition of Jab1/CSN5 is sufficient to impact on prolif-
eration and potentially other properties of tumors and
warrants further investigation as a cancer therapeutic.
Conclusion
Jab1/CSN5’s multiple functions affect a number of pro-
teins and signaling pathways, and the results of these
interactions are generally oncogenic. The strong correla-
tion between Jab1/CSN5 overexpression and low p27
levels and poor prognosis in a variety of human cancers
underscores the importance of Jab1/CSN5 in carcino-
genesis. However, the exact role that Jab1/CSN5 plays
in oncogenic processes and which of its many functions
contributes to these processes is far from being fully
understood. It would be interesting to determine
whether Jab1/CSN5 contributes to tumorigenesis
through one specific interaction or the accumulation of
multiple interactions. Further, whether these interactions
are dependent on Jab1/CSN5’s existence as either a
member of the COP9 signalosome holo-complex or a
member of smaller complexes outside the COP9 signa-
losome, which contain other members of the CSN, or
its presence as a monomer, has yet to be clarified.
The physiologic significance of Jab1/CSN5 in cancer is
highlighted by the wide range of cancers in which it is
overexpressed. Yet the molecular mechanism by which
Jab1/CSN5 is involved in the myriad of protein interac-
tions remains to be more clearly identified. No particu-
lar protein domain identified within these proteins links
them in any way. The JAMM domain is certainly impor-
tant for cleavage of cullin-Nedd8 conjugates and repre-
sent a major player in cellular regulation, but it does
not appear to be the key domain for all Jab1/CSN5
interactions. It has been suggested that a post-transla-
tional modification or possibly a redox-induced protein
modification leads to a Jab1/CSN5 interaction; this war-
rants further investigation [101]. A link between the
Table 3 Cancers in which Jab1/CSN5 is overexpressed and its association with p27 and clinical outcome
Tumor type Associated with poor outcome Negative Correlation with p27 References
Pituitary tumor No Yes [121]
Pancreatic adenocarcinoma Yes Yes [100,122]
Oral squamous cell carcinoma Yes Yes [123,124]
Epithelial ovarian tumors Yes Yes [125,126]
Neuroblastoma ND ND [127]
Embryonal rhabdomyosarcoma No Yes [128]
Hepatocellular carcinoma ND Yes [83,97,107]
Intrahepatic Cholangiocarcinomas No No [129]
Laryngeal squamous cell carcinoma Yes Yes [130]
Esophageal squamous cell carcinoma Yes Yes [131]
Metastatic melanoma ND Yes [132]
Invasive breast carcinoma Yes Yes [92,93]
ERalpha-negative breast cancer No No [98]
Systemic anaplastic large cell lymphoma ND Yes [133]
Non-Hodgkin’s lymphoma Yes Yes [134]
Malignant lymphoma of the thyroid ND Yes [135]
Thyroid medullary carcinoma No Yes [136]
Papillary Thyroid Carcinoma Yes ND [137]
Non-small-cell lung cancer Yes Yes [138,139]
Abbreviation: ND, not determined.
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Page 10 of 14Ras/MAPK and PI3K/AKT pathways, which were
detected through Bcr-Abl signaling, has been identified.
Understanding the mechanisms of activation will be cri-
tical for understanding the regulation of Jab1/CSN5’s
functions. These mechanisms also involve interactions
between the CSN and other large protein complexes as
have been demonstrated with I-B kinases and sug-
gested to occur with nuclear receptors and their coacti-
vators [37,102].
Much remains unclear about Jab1/CSN5, but what is
clear is that its overexpression is involved in the devel-
opment of cancer and that further investigation of Jab1/
CSN5 as a therapeutic target may lead to the develop-
ment of a powerful cancer therapeutic for use in a wide
range of tumors.
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